Ras/mapk pathway vascular anomalies

Clinical trials for Ras/mapk pathway vascular anomalies explained in plain language.

Never miss a new study

Get alerted when new Ras/mapk pathway vascular anomalies trials appear

Sign up with your email to follow new studies for Ras/mapk pathway vascular anomalies, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Cancer drug shows promise for rare blood vessel disorders

Disease control Ongoing

This phase 2 trial tests the drug trametinib in 45 people aged 2 months to 30 years with vascular anomalies caused by changes in the Ras/MAPK pathway. Participants take trametinib daily for up to 3 years. The study measures whether the drug shrinks lesions, improves quality of li…

Matched conditions: RAS/MAPK PATHWAY VASCULAR ANOMALIES

Phase 2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control

Last updated Jun 27, 2026 12:23 UTC

Ras/mapk pathway vascular anomalies

Get alerted when new Ras/mapk pathway vascular anomalies trials appear

Cancer drug shows promise for rare blood vessel disorders